Table 5.
Parameter | e-CuidateChemo group (n=19) | Control group (n=20) | Between-groups effects | |
Waist circumference (cm) | ||||
Baseline | 85.20 (11.66); 79.81-90.74 | 86.10 (8.70); 82.02-90.17 | N/Aa | |
8-week intervention | 86.01 (11.07); 80.83-91.19 | 86.28 (10.88); 81.19-91.37 | N/A | |
Within-group effect - baseline to 8 weeks | 0.73 (3.41); –0.86 to 2.33 | 0.18 (3.47); –1.43 to 1.80 | –0.55; –2.75 to 1.65 | |
Hip circumference (cm) | ||||
Baseline | 101.58 (9.59); 97.08-106.07 | 103.82 (8.74); 99.72-107.91 | N/A | |
8-week intervention | 102.72 (8.60); 98.69-106.75 | 103.50 (9.59); 99.01-107.99 | N/A | |
Within-group effect - baseline to 8 weeks | 1.14 (3.20); –0.35 to 2.64 | –0.31 (1.88); –1.19 to 0.56 | –1.46; –3.14 to 0.22 | |
Weight (kg) | ||||
Baseline | 66.46 (12.29); 60.70-72.21 | 67.82 (10.47); 62.91 to 72.72 | N/A | |
8-week intervention | 67.35 (11.27); 62.07-72.62 | 68.20 (11.71); 62.72 to 73.68 | N/A | |
Within-group effect - baseline to 8 weeks | 0.89 (2.89); –0.46 to 2.24 | 0.38 (2.57); –0.82 to 1.59 | –0.50; –2.26 to 1.25 | |
Body fat (%) | ||||
Baseline | 32.90 (9.60); 28.41-37.39 | 35.01 (7.32); 31.57-38.43 | N/A | |
8-week intervention | 33.41 (9.01); 29.19-37.63 | 33.13 (6.69); 29.99-36.26 | N/A | |
Within-group effect - baseline to 8 weeks | 0.51 (2.17); –0.50 to 1.52 | –1.87 (7.04); –5.17 to 1.42 | –2.38; –5.72 to 0.95 | |
Lean mass (kg) | ||||
Baseline | 23.84 (2.61); 22.61-25.06 | 23.76 (3.15); 22.28-25.23 | N/A | |
8-week intervention | 23.93 (2.75); 22.64-25.22 | 23.93 (3.32); 22.37-25.48 | N/A | |
Within-group effect - baseline to 8 weeks | 0.09 (1.05); –0.39 to 0.58 | 0.17 (1.05); –0.32 to 0.66 | 0.07; –0.59 to 0.74 | |
Body mass index (kg/m2) | ||||
Baseline | 26.31 (4.97); 23.98-28.63 | 26.79 (3.79); 25.01-28.56 | N/A | |
8-week intervention | 26.64 (4.58); 24.49-28.78 | 26.89 (4.32); 24.87-28.91 | N/A | |
Within-group effect - baseline to 8 weeks | 0.33 (1.09); –0.18 to 0.84 | 0.10 (1.02); –0.37 to 0.58 | –0.22; –0.90 to 0.45 |
aN/A: not applicable.